Carnosine Supplement Targets Neuromuscular Decline in Multiple Sclerosis
A completed pilot trial tests whether 2g/day of a novel carnosine formulation can restore neuromuscular function and quality of life in MS patients.
Summary
Multiple sclerosis is linked to depleted tissue carnosine and mitochondrial dysfunction, both of which may drive the fatigue and neuromuscular decline that severely limit MS patients' quality of life. Researchers at the University of Novi Sad tested Karnozin EXTRA, a novel carnosine formulation designed to overcome the poor bioavailability that has hampered past versions, at a dose of 2 grams per day over eight weeks. The trial measured neuromuscular performance, brain biomarkers of carnosine metabolism, and health-related quality of life in a case series of MS patients. This is reportedly the first human study to evaluate an innovative carnosine formulation in this population, making it a meaningful step toward understanding whether correcting carnosine deficits could be a practical therapeutic tool in MS management.
Detailed Summary
Multiple sclerosis is a chronic neuroinflammatory and neurodegenerative disease that leaves many patients struggling with progressive fatigue, muscle weakness, and declining quality of life. Beneath these symptoms lies a metabolic problem: MS appears to deplete tissue carnosine, a naturally occurring dipeptide critical for buffering oxidative stress and supporting mitochondrial energy production. Correcting this deficit has been an appealing therapeutic target, but prior carnosine formulations have struggled with poor bioavailability, particularly in reaching brain and muscle tissue at meaningful concentrations.
This completed clinical trial from the University of Novi Sad set out to test whether Karnozin EXTRA, a novel carnosine formulation engineered for improved tissue delivery, could make a measurable difference. MS patients received 2 grams of oral carnosine daily for eight weeks in a case series design. Outcomes included neuromuscular performance testing, brain biomarkers of carnosine metabolism, and patient-reported quality of life measures.
Because only the abstract is publicly available, specific results — effect sizes, biomarker changes, and quality of life scores — cannot be reported. What is known is that the trial was completed, suggesting feasibility and adequate tolerability in this patient population, which is itself a meaningful signal for future research.
The implications are potentially significant. Carnosine's dual role as an antioxidant and mitochondrial support agent makes it mechanistically attractive for MS, where both oxidative stress and energy failure are implicated in neurodegeneration. If an optimized formulation can reliably reach target tissues, it could offer a low-risk, accessible adjunct to standard MS therapy.
Caveats are substantial. The case series design limits generalizability and prevents causal conclusions. The trial was not randomized or placebo-controlled. Full results have not been published in a peer-reviewed journal as of this summary. All conclusions should be treated as preliminary until complete data are available.
Key Findings
- MS patients show depleted tissue carnosine levels linked to mitochondrial dysfunction and oxidative stress.
- Karnozin EXTRA (2g/day, 8 weeks) was tested as the first innovative carnosine formulation studied in humans with MS.
- Trial assessed neuromuscular performance, brain carnosine biomarkers, and health-related quality of life.
- Trial was completed, suggesting the protocol was feasible and likely tolerable in MS patients.
- Standard carnosine supplements have poor bioavailability; novel formulations may be needed for clinical efficacy.
Methodology
This was a case series design — not randomized or placebo-controlled — enrolling MS patients at the University of Novi Sad. Participants received 2g/day oral carnosine (Karnozin EXTRA) for 8 weeks. Outcomes spanned neuromuscular function, brain carnosine metabolism biomarkers, and quality of life questionnaires.
Study Limitations
This summary is based on the abstract only; full results, effect sizes, and safety data are unavailable. The case series design lacks a control group and randomization, severely limiting causal inference. The small, uncontrolled nature of the trial means findings cannot be generalized until confirmed in a properly powered, randomized controlled trial.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.